Proline Charge at pH 7 in a Peptide Bond: Key Data on Its Neutral Zwitterion State and Impact on 2006 Peptide Drug Design
Title: Proline Charge at pH 7 in a Peptide Bond: Key Data on Its Neutral Zwitterion State and Impact on 2006 Peptide Drug Design Abstract: At pH 7, proline within a peptide bond exists as a neutral zwitterion (pKa 10.6 for α-NH₃⁺; no side-chain charge), critically influencing peptide drug design since 2006. This neutral state enhances conformational rigidity and metabolic stability, reducing renal clearance. In the 2024 peptide market (projected $50B CAGR 8.5%), brands leveraging proline’s charge neutrality (e.g., semaglutide, liraglutide) dominate GLP-1 agonists. Key advantages include improved oral bioavailability and resistance to proteolysis; disadvantages include synthesis complexity and higher cost. Product comparisons show proline-rich peptides exhibit 30% longer half-life vs. non-proline analogs. Industry trends favor cyclic peptides with proline turns for targeted therapeutics. Certifications (GMP, ISO 9001) and factory audits ensure purity >98%. Logistics require cold chain (-20°C) to maintain zwitterion stability. Selection criteria prioritize proline content for enhanced pharmacokinetics.